zabilugene almadenorepvec
AXP000008.2 · Oncolytic virus
- Platform
- adenovirus (Ad5, RGD-modified capsid, E2F-responsive E1A)
- Originator
- VCN Biosciences
- Sponsor
- Theriva Biologics
Names
Virus
- Role
- Oncolytic
- Family
- Adenoviridae
- Virus
- human adenovirus 5 (NCBI Taxonomy 28285)
- Strain
- Ad5 (VCN-01)
- Replication
- conditionally replicating
- Modifications
- E2F-responsive E1A with Delta-24; RGD-modified fiber; replaced E1A Sp1 sites
- Transgenes
- SPAM1
- Route
- intravenous, intratumoral, intravitreal
- Source
- evidence
Cross-references
- NCI Thesaurus
- C211709
- FDA UNII
- 3HBM7CA87P
Approvals
No regulatory approval recorded.
Clinical trials (7)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07701486 | A Study of More Frequent Dosing of VCN-01 Combined With Standard Chemotherapy in Patients With Newly Diagnosed Metastatic Pancreatic Cancer | Recruiting | Phase 1/2 | 2026-07-31 | 2027-08-01 | 6 | Ductal Adenocarcinoma of the Pancreas; Pancreas Cancer, Metastatic; Pancreas Cancer, Stage IV |
| NCT05673811 | Study of Nab-Paclitaxel and Gemcitabine and Plus/Minus VCN-01 in Patients With Metastatic Pancreatic Cancer | Completed | Phase 2 | 2023-01-10 | 2025-03-28 | 112 | Metastatic; Pancreatic Adenocarcinoma |
| NCT05057715 | huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer | Terminated | Phase 1 | 2022-03-02 | 2026-04-29 | 13 | Pancreatic Cancer; Serous Ovarian Cancer |
| NCT03799744 | Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | Unknown | Phase 1 | 2019-03-20 | 2023-01-31 | 20 | Carcinoma, Squamous Cell of Head and Neck; Head and Neck Neoplasms; Metastasis; Recurrence |
| NCT03284268 | Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma | Completed | 2017-09-06 | 2024-06-14 | 13 | Retinoblastoma, Recurrent | |
| NCT02045602 | Phase I Dose Escalation Study of Intravenous VCN-01 With or Without Gemcitabine and Abraxane® in Patients With Advanced Solid Tumors | Completed | Phase 1 | 2014-01 | 2019-05 | 42 | Locally Advanced Solid Tumors; Metastatic Solid Tumors; Pancreatic Adenocarcinoma |
| NCT02045589 | A Phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane® in Patients With Advanced Pancreatic Cancer | Completed | Phase 1 | 2014-01 | 2016-10 | 8 | Metastatic Pancreatic Adenocarcinoma; Pancreatic Adenocarcinoma |
Recent changes
No changes recorded in its trials yet.
Clinical papers
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 42257887 | Phase I Trial of Intravenous VCN-01 Oncolytic Adenovirus and Durvalumab in Patients with Head and Neck Metastatic Squamous Cell Carcinoma Refractory to Immunotherapy. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2026 | name in title: VCN-01 |
| PMID 42816596 | Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. | Nature medicine | 2026 | cited by trial NCT05673811 |
| PMID 35338084 | Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors. | Journal for immunotherapy of cancer | 2022 | cited by trial NCT02045602 |
| PMID 35149591 | VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. | Journal for immunotherapy of cancer | 2021 | cited by trial NCT02045589 |
| PMID 30674657 | Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. | Science translational medicine | 2019 | name in title: VCN-01 |
Other papers
Preclinical studies, reviews and other papers that name it.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 40880319 | Toxicity and Biodistribution of the Oncolytic Virus VCN-01 Following Intracranial Injection in Syrian Hamsters. | Human gene therapy | 2025 | name in title: VCN-01 |
| PMID 31591461 | The oncolytic adenovirus VCN-01 promotes anti-tumor effect in primitive neuroectodermal tumor models. | Scientific reports | 2019 | name in title: VCN-01 |
| PMID 26603261 | The Oncolytic Adenovirus VCN-01 as Therapeutic Approach Against Pediatric Osteosarcoma. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2016 | name in title: VCN-01 |
| PMID 26808201 | Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. | PloS one | 2016 | name in title: VCN-01 |
| PMID 27280773 | Correction: Characterization of the Antiglioma Effect of the Oncolytic Adenovirus VCN-01. | PloS one | 2016 | name in title: VCN-01 |
| PMID 25391696 | Safety and efficacy of VCN-01, an oncolytic adenovirus combining fiber HSG-binding domain replacement with RGD and hyaluronidase expression. | Clinical cancer research : an official journal of the American Association for Cancer Research | 2015 | name in title: VCN-01 |
Unconfirmed matches (3)
Found by a weaker match (an ambiguous or short name, or a name only in the abstract); not counted. Corrections welcome.
| PubMed | Title | Journal | Year | Linked by |
|---|---|---|---|---|
| PMID 37749907 | Oncolytic virotherapies for pediatric tumors. | Expert opinion on biological therapy | 2023 | name in abstract: VCN-01 |
| PMID 34377767 | Hyaluronidase expression within tumors increases virotherapy efficacy and T cell accumulation. | Molecular therapy oncolytics | 2021 | name in abstract: VCN-01 |
| PMID 30497448 | Assessment of metabolic patterns and new antitumoral treatment in osteosarcoma xenograft models by [18F]FDG and sodium [18F]fluoride PET. | BMC cancer | 2018 | name in abstract: VCN-01 |
Notes
Transgene is human PH20 hyaluronidase; HGNC symbol for PH20 is SPAM1 (curator mapping). VCN Biosciences spun out of ICO-IDIBELL and was acquired by Synthetic Biologics in 2022, which renamed itself Theriva Biologics. Transgenes moved from targets to virus.tsv (spec 0.2).
How to cite
zabilugene almadenorepvec (AXP000008.2). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000008.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.